Cargando…
Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria
BACKGROUND: Treatments for uncomplicated falciparum malaria should have high cure rates. The World Health Organization has recently set a target cure rate of 95% assessed at 28 days. The use of more effective drugs, with longer periods of patient follow-up, and parasite genotyping to distinguish rec...
Autores principales: | Stepniewska, Kasia, White, Nicholas J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1769507/ https://www.ncbi.nlm.nih.gov/pubmed/17187673 http://dx.doi.org/10.1186/1475-2875-5-127 |
Ejemplares similares
-
Revisiting the Design of Phase III Clinical Trials of Antimalarial Drugs for Uncomplicated Plasmodium falciparum Malaria
por: Borrmann, Steffen, et al.
Publicado: (2008) -
Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria
por: Ashley, Elizabeth A., et al.
Publicado: (2010) -
A systematic review of published antimalarial clinical trials: parasite clearance of artemisinin-containing regimens in the treatment of uncomplicated malaria
por: Das, Debashish, et al.
Publicado: (2012) -
Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children
por: Maiteki-Sebuguzi, Catherine, et al.
Publicado: (2008) -
Statistical methods to derive efficacy estimates of anti-malarials for uncomplicated Plasmodium falciparum malaria: pitfalls and challenges
por: Dahal, Prabin, et al.
Publicado: (2017)